Aim: Alpha7-nicotinic acetylcholine receptor (α7 nAChR) is a ligand-gated Ca 2+ -permeable ion channel implicated in cognition and neuropsychiatric disorders. Activation of α7 nAChR improves learning, memory, and sensory gating in animal models. To identify novel α7 nAChR agonists, we synthesized a series of small molecules and characterized a representative compound, Br-IQ17B, N-[(3R)-1-azabicyclo[2,2,2]oct-3-yl]-5-bromoindolizine-2-carboxamide, which specifically activates α7 nAChR. Methods: Two-electrode voltage clamp (TEVC) recordings were primarily used for screening in Xenopus oocytes expressing human α7 nAChR. Assays, including radioisotope ligand binding, Western blots, whole-cell recordings of hippocampal culture neurons, and spontaneous IPSC recordings of brain slices, were also utilized to evaluate and confirm the specific activation of α7 nAChR by Br-IQ17B. Results: Br-IQ17B potently activates α7 nAChR with an EC 50 of 1.8±0.2 μmol/L. Br-IQ17B is selective over other subtypes such as α4β2 and α3β4, but it blocks 5-HT 3A receptors. Br-IQ17B displaced binding of the α7 blocker [
Introduction
The nicotinic acetylcholine receptors (nAChRs) are pentameric integral membrane proteins that belong to a superfamily of ligand-gated ion channels including serotonin 5-HT 3 receptor and GABA A receptor. The nAChRs form non-selective cation channels composed of either homomeric α-or heteromeric α/β subunits [1] . The specific assembly of nAChR subunits determines the biophysical and pharmacological properties of the channel receptor. For instance, homomeric α7 nAChR is characterized by its high calcium permeability (P Ca :P Na ≈10), its rapid desensitization in the presence of agonists, and its inhibition by the antagonists α-bungarotoxin and methyllycaconitine (MLA) [2, 3] . The α7 nAChR is a homopentameric receptor in the mammalian central nervous system (CNS) with limited peripheral expression, thus reducing potential side effects from inhibition. The α7 nAChR is highly expressed in the brain regions that are critical for cognition, attention processing, and memory formation, particularly in the hippocampus and frontal cortex [2] . The localization of α7 nAChR is both presynaptic and postsynaptic, and nAChR is involved in numerous processes, including the modulation of neurotransmitter release [4] , the regulation of postsynaptic excitability [5] , and hippocampal synaptic plasticity [6] . The disruption of α7 nAChR activity has been implicated in the pathophysiology of neuropsychiatric conditions such as Alzheimer's disease (AD) and schizophrenia. Genetic studies show that the α7 nAChR gene CHRNA7, which is located on chromosome 15q14, is linked with sensory gating deficits in schizophrenic patients [7] . The analysis for association of promoter variants in the CHRNA7 gene with schizophrenia shows an inhibitory deficit of P50 auditory evoked potential response from schizophrenics and decreased function of transcription from the gene [8] . In biochemical experiments, the analysis of postmortem tissue reveals a marked reduction of α7 nAChR protein levels in various brain regions of schizophrenics [9] . In DBA/2 mice, hippocampal α7 nAChR density is closely correlated with sensory gating, and low α-bungarotoin binding is associated with poor gating [10] . Knocking out α7 nAChR in mice results in a comparable deficit in sustained attention, a characteristic symptom of schizophrenia, when compared to WT mice [11] . For AD, the levels of α7 nAChR proteins are decreased in the hippocampus of AD patients [12] . β-Amyloid peptide (Aβ ) binds selectively to neuronal α7 nAChR with picomolar affinity in neuritic plaques [13] , leading to the intraneuronal accumulation of Aβ 1-42 and α7 nAChR complexes [14] , rapid tau phosphorylation [15] , the reversible blocking of the α7 nAChR channel [16] , the disruption of calcium homeostasis, and neuronal cell death [17] , whereas α7 activation confers neuroprotection against Aβ-induced cellular toxicity [18] . Therefore, a hypothesis has been proposed that the pharmacological activation of α7 nAChR can serve as potential therapy for the treatment of schizophrenia and AD. A number of distinct α7 agonists have been identified and tested in the early phases of clinical trials. Positive phase II clinical data were previously reported with EVP-6124 ((R)-7-chloro-N-quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide) and TC-5619 ((2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl] benzo[b]furan-2-carboxamide) for improving the symptoms of schizophrenia. When combined with atypical antipsychotic treatment, both EVP-6124 and TC-5619 show beneficial effects on cognition and are generally well tolerated in subjects with stable schizophrenia [19] [20] [21] . However, there are several α7 agonists that have failed in clinical trials due to adverse events related to cardiovascular and gastrointestinal functions, lack of efficacy, or an insufficient therapeutic index [22] [23] [24] , thus indicating the need to identify novel chemicals that can selectively activate α7 nAChR.
In this study, we described a novel, selective α7 nAChR partial agonist, Br-IQ17B, (N-[(3R)-1-azabicyclo[2,2,2]oct-3-yl]-5-bromoindolizine-2-carboxamide) identified from indolizine derivatives using electrophysiology as a primary functional screen. With radioisotope binding assays, brain slice recordings, and Western blotting, we confirmed that Br-IQ17B selectively activates α7 nAChR function with high-affinity binding to α7 nAChR and displays weak interactions with non-α7 nAChR subtypes. The Br-IQ17B activity was further confirmed by its activation of α7 nAChR in native neurons and its improvement of synaptic transmissions recorded from hippocampal brain slices. Our findings demonstrate a selective and novel α7 agonist, Br-IQ17B, that activates α7 currents both in hetero-expression system and neurons. Br-IQ17B can be a helpful pharmacological tool in understanding new aspects of α7 nAChR functionality, and it may lead to the development of therapy for neuropsychiatric disorders such as AD and schizophrenia. For two-electrode voltage clamp recordings in oocytes, capped cRNAs were transcribed in vitro using the T3 mMESSAGEmMACHINE Kit (Ambion, Austin, TX, USA) following the linearization of plasmids in pBluescript KSM vectors. The oocytes were injected with 46 nL of cRNA solution containing approximately 20 ng human α7 nAChR cRNA or approximately 1 ng human 5-HT 3A cRNA using a microinjector (Drummond Scientific, Broomall, PA, USA). For the expression of heteromeric rat α3β4 and rat α4β2 nAChRs, approximately 2 ng total cRNAs were injected in a 1:1 combination of each subunit. For GABA A receptors, cRNAs encoding α1, 2-, 3-or 5-, β3, and γ2 were mixed in a ratio of 1:1:1 and microinjected into oocytes to a total of approximately 1.5 ng. Oocytes were kept at 17 °C in ND96 solution (96 mmol/L NaCl, 2 mmol/L KCl, 1.8 mmol/L CaCl 2 , 1 mmol/L MgCl 2 , 5 mmol/L HEPES, pH 7.4 adjusted with NaOH).
Materials and methods

Chemicals
Recordings were made 2-5 days post-injection. Oocytes were impaled with two microelectrodes (0.5-1.0 MΩ) filled with 3 mol/L KCl in a 40-μL recording chamber. The membrane potential was held at -90 mV using standard voltage clamp procedures. Currents were recorded in Ringer's solution (115 mmol/L NaCl, 2.5 mmol/L KCl, 10 mmol/L HEPES, 1.8 mmol/L CaCl 2 , 1 mmol/L MgCl 2 , 0.0005 mmol/L atropine) at room temperature (22±1 °C) using a GeneClamp 500B amplifier (Axon Instruments, Union City, CA, USA).
Radioisotope ligand binding assay in crude membranes
Cerebral hippocampi from male Sprague-Dawley rats weighing 230 to 250 g were placed in 0.32 mol/L ice-cold sucrose containing protease inhibitors (Protease Inhibitor Cocktail Tablets; Roche Diagnostics, Indianapolis, IN, USA) (one tablet per 50 mL). For crude membrane preparations, brain tissues were homogenized and centrifuged at 1000×g at 4 °C for 10 min. The supernatant was centrifuged for 10 min at 20 000×g at 4 °C, and the pellet was washed twice by centrifugation at 40 000×g for 10 min. Crude membranes were stored at -80 °C until use.
The saturation binding for α7 nAChR was performed in a final volume of 500 μL binding buffer (120 mmol/L NaCl, Western blot analysis PC12 cells were starved overnight in serum-free medium to reduce basal phosphorylation. After treatment with compounds, reactions were terminated by placing the culture dish on ice and removing the incubation medium by aspiration. Cells were washed twice with D-PBS and treated with ice-cold lysis buffer (150 mmol/L NaCl, 20 mmol/L Tris, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 10 mmol/L EDTA, pH 8.0), supplemented with protease inhibitor mixtures (Protease Inhibitor Cocktail Tablets; Roche Diagnostics, Indianapolis, IN, USA) on ice for 30 min. Cell lysates were then centrifuged at 13 000×g for 20 min to yield protein extracts in the supernatant.
For Western blots, protein samples were separated on SDSpolyacrylamide gel and transferred electrophoretically onto nitrocellulose membranes (Millipore, Boston, MA, USA). After being blocked with the 5% powdered nonfat milk or 5% BSA in TBS-T (Tris-buffered saline with 0.05% Tween 20), cell membranes were incubated overnight at 4 °C with primary antibodies (1:1000 for anti-ERK from Cell Signaling Technology; 1:2000 for anti-pERK from Cell Signaling Technology, Boston, MA, USA). The membranes were then incubated with their corresponding secondary HRP-conjugated antibodies and detected using an ECL Western blotting detection system (Millipore, Boston, MA, USA). Densitometric analysis was performed using a Bio-Rad image acquisition system (Bio-Rad Laboratories, Hercules, CA, USA).
Culture of hippocampal neurons and whole-cell patch-clamp Hippocampal explants were isolated from embryos of 18-dayold Sprague-Dawley rats of either sex after decapitation. Hippocampal regions were gently removed and digested with 0.25% trypsin for 30 min at 37 °C followed by trituration with a pipette in plating medium (DMEM with 10% FBS). Dissociated neurons were plated onto poly-D-lysine coated coverslips in 35-mm dishes at a density of 1×10 6 cells per dish. After 4 h, the medium was displaced by neurobasal medium supplemented with 2% B27 and 0.5 mmol/L GlutaMAX-I (Life Technologies, Carlsbad, CA, USA).
For whole-cell recordings, cells were held at -80 mV and recorded using a HEKA EPC10 amplifier with PatchMaster software (HEKA Elektronik, Pfalz, Germany). Patch pipettes were pulled from borosilicate glass and fire-polished to a resistance of 3-5 MΩ when filled with internal pipette solution 
Hippocampal brain slice electrophysiology
Male Sprague-Dawley rats (14-21 day-old) were deeply anesthetized with sodium pentobarbital (250 mg/kg) before decapitation. Brains were quickly removed and placed into ice-cold artificial cerebrospinal fluid (ACSF) containing (in mmol/L): 119 NaCl, 2.5 KCl, 2.5 CaCl 2 , 1.3 MgSO 4 , 1 NaH 2 PO 4 , 26.2 NaHCO 3 , and 11 glucose, and bubbled with 95% O 2 /5% CO 2 . Transverse hippocampal slices (400 μm) were cut with a vibratome (Leica VT1200S, Leica, Wetzlar, Germany). The slices were incubated for 1 h at 34 °C with ACSF and then transferred to a recording chamber on an upright microscope equipped with differential interference contrast (DIC) optics (Nikon FN1, Tokyo, Japan). For IPSC recordings, whole-cell patch clamp configurations were routinely achieved from CA1 hippocampal pyramidal neurons visualized with a DIC microscope. Patch pipette (3-5 MΩ) solution contained (in mmol/L): 136 CsCl, 4 NaCl, 1 MgCl 2 , 0.5 CaCl 2 , 5 EGTA, 10 HEPES, 3 Mg-ATP, 0.3 GTP-Na, 4-phosphocreatine (pH adjusted to 7.2 with CsOH and osmolarity adjusted to 290 mOsm). According to the Nernst equation, the reversal potential of Cl -was approximately 3 mV at room temperature.
Therefore, when neurons were held at -70 mV, the spontaneous IPSCs were inward. To block fast excitatory synaptic current (EPSC), 5 μmol/L CNQX (in DMSO) and 10 μmol/L APV were added to ACSF. Atropine (5 μmol/L) was used to block muscarinic receptors. Voltage-clamp recordings were conducted with a computer-controlled amplifier (Multiclamp 700B, Molecular Devices, Sunnyvale, CA, USA), and traces were low-pass filtered at 2.6 kHz and digitized at 10 kHz (DigiData 1440A, Molecular Devices, Sunnyvale, CA, USA).
Neurons with stable access resistance were included in the analysis.
Data analysis
All data are expressed as the mean±SEM. Statistical significance was assessed by Student's t-test or one-way ANOVA using Prism version 5.0 software. A value of P<0.05 was considered statistically significant. In two-electrode voltage clamp and whole-cell patch clamp recordings, responses were quantified by measuring peak current amplitude, and data were collected and analyzed using PatchMaster and Origin 8.0 software. For hippocampal brain slice electrophysiology, the data were collected and analyzed using Clampfit 10.4 or Clampex 10.4 software. All concentration-response curves were fitted to the Hill equation as follows:
. For radioisotope ligand binding assay, the dissociation constant K i was determined from the equation
Results
Screening α7 nAChR agonists by two-electrode voltage clamp
To identify novel α7 agonists, we started with a computeraided virtual screen and performed structural optimizations using the compound EVP-6124, which is in a phase II clinical trial, as a reference structure [21] . The substructure search for α7 nAChR agonists from the SureChEMBL database revealed that N-(quinuclidin-3-yl) formamide appeared frequently, and its similarity search (SS) was performed based on the MACCS structural fingerprint [25] . Approximately 400 compounds were selected, and they clustered into 20 categories. Among the SS-selected compounds, an indolizine-3-carboxylic acid derivative was reported to block the 5-HT 3 receptor, which shares significant homology with α7 nAChR [26, 27] . Thus, an indolizine-3-carboxylic acid derivative was used as a hit for structural modifications that were primarily focused on the indolizine moiety by changing the substitution group at different positions. Over 60 compounds were synthesized, and their activities were tested on human α7 nAChR transiently expressed in Xenopus oocytes using two-electrode voltage clamp. Compounds that were able to evoke α7 currents were further assessed for their potency and relative efficacy against acetylcholine. EC 50 values of positive compounds were generated by fitting Hill equations, and their maximal effects were normalized to 3 mmol/L ACh from the same cell. Based on the criteria that compounds must have a minimal EC 50 and an efficacy of at least 60% that of ACh, one compound, N-[(3R)-1-azabicyclo[2,2,2]oct-3-yl]-5-bromoindolizine-2-carboxamide (Br-IQ17B, MW=348.24) was identified as an ideal lead ( Figure  1A ). Therefore, Br-IQ17B was further evaluated for its effects on α7 currents.
Dose-dependent activation of α7 currents by Br-IQ17B
As shown in Figure 1B , the activation of α7 by ACh was first performed as a control before repeated applications of Br-IQ17B. With a 7-min pulse interval between each dose, increasing concentrations of Br-IQ17B dose-dependently activated α7 nAChR with a maximum efficacy of 64.3%±3.6% compared with 3 mmol/L ACh ( Figure 1C) . The data from dose-dependent activation were fitted with the Hill equation, yielding an EC 50 of 1.8±0.2 µmol/L and a Hill coefficient of 1.2±0.1 (n=6) ( Figure 1C ). The current induced by Br-IQ17B (30 µmol/L) was completely blocked by 10 nmol/L MLA, an α7 nAChR selective antagonist ( Figure 1D ), indicating that Br-IQ17B mediated its effects through specific α7 activation. To further confirm the agonist activity of Br-IQ17B, we tested Br-IQ17B in the presence of the α7 positive allosteric modulator (PAM) PNU-120596, which is known to enhance the activation of α7 by ACh [28] . As shown in Figure 2A , co-application of Br-IQ17B with a fixed concentration of PNU-120596 (1 mmol/L) resulted in a dose-dependent activation of α7 currents. The potency of Br-IQ17B was increased from 1.8±0.2 µmol/L to 93.6±6.5 nmol/L (n=6), and the Hill slope was increased from 1.2±0.1 to 2.4±0.1 compared with Br-IQ17B alone, which showed partial activation ( Figure 2B) .
One of the key properties of α7 current is robust desensitization upon repeated exposures to an agonist [29] . To test whether Br-IQ17B could cause desensitization, we used a double protocol in which oocytes were exposed to sustained (1 min) increasing concentrations of Br-IQ17B before the addition of a fixed and low concentration of ACh (100 µmol/L). As shown in Figure 2C , 100 µmol/L ACh produced a robust α7 current. In contrast, the incubation of different concentrations of Br-IQ17B decreased the amplitude of α7 current in the presence of the same concentration of ACh (100 µmol/L). Plotting the amplitude of the current evoked by ACh as a function of increasing Br-IQ17B yielded a concentrationdependent inhibition of ACh-induced α7 current with an IC 50 at 28.5±1.9 nmol/L and a Hill coefficient at 2.8±0.3 (Figure 2D) , which is in good agreement with the K i of 14.9±3.2 nmol/L for the displacement of [
3 H]-MLA binding at α7 nAChR. It is noteworthy that the low concentration of Br-IQ17B (3 nmol/L) that had no agonist activity increased the ACh-mediated peak current, whereas the current desensitization became apparent for Br-IQ17B at 10 nmol/L or greater concentration ( Figure 2C and 2D ).
Displacement of [
3 H]-MLA binding to α7 nAChR by Br-IQ17B α7 nAChR agonists can displace the binding of the specific competitive antagonist [ 3 H]-MLA to the α7 nAChR extracellular N-terminal domain, which contains the orthosteric binding sites [30] . To assess whether Br-IQ17B could affect [ 3 H]-MLA binding, we prepared hippocampal crude membranes from rat hippocampi that contain nAChRs and conducted the . PNU-282987, a selective α7 nAChR agonist, is known to bind to α7 nAChR [31] . As another positive control, the inhibitory effect of PNU-282987 on [
3 H]-MLA binding was determined. PNU-282987 dose-dependently displaced the binding of [
3 H]-MLA with a K i of 34.1±4.3 nmol/L, which is similar to the K i value as previously described [32] . These results show that Br-IQ17B can competitively bind to α7 nAChR.
Selective activation of α7 by Br-IQ17B
To determine the selectivity of Br-IQ17B, we examined the effects of Br-IQ17B on α4β2 and α3β4, two nAChR subtypes that exhibit distributions that are similar to that of α7 nAChR in the brain [33] . The expression of rat α4β2 or α3β4 in Xenopus oocytes produced a robust current in response to either 100 or 300 mmol/L ACh ( Figure 4A and 4B). The application of Br-IQ17B (100 mmol/L) did not induce any current ( Table 1) . The lack of effect on α4β2 was further confirmed by either preincubation of Br-IQ17B for 1 min or the co-application of Br-IQ17B with ACh, which resulted in no enhancement or inhibition of α4β2 current ( Figure 4A ). This result indicates that 
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Acta Pharmacologica Sinica npg Br-IQ17B had no effect on α4β2. For α3β4, Br-IQ17B showed an inhibitory effect with an IC 50 of approximately 381.5±28.6 µmol/L and a Hill coefficient of 0.9±0.1 (n=5) (Figure 4B ), thus displaying at least 300-fold selectivity over α3β4 ( Figure 4C ). The 5-HT 3A receptor has significant homology with α7 nAChR and serves as a cross-reactivity target for α7 agonists. Br-IQ17B alone (0.1-100 µmol/L) did not show any agonist activities on human 5-HT 3A receptors expressed in oocytes. The co-application of Br-IQ17B with serotonin dose-dependently inhibited the current induced by 5-HT (10 µmol/L) with an IC 50 of 3.74±0.64 µmol/L (n=6) and a Hill coefficient of 2.1±0.1 ( Figure 4D and 4E, Table 2 ).
Activation of native neuronal α7 nAChR by Br-IQ17B
Hippocampal somatic neurons express α7 nAChR or AChevoking characteristic α7 currents that can be activated by α7 agonists [34] . To evaluate whether Br-IQ17B can activate native α7 nAChR, we examined the effects of Br-IQ17B on hippocampal neurons. As shown in Figure 5A , the application of either ACh (1 mmol/L) or Br-IQ17B (10 µmol/L) evoked α7 currents with fast onset and rapid decay. Br-IQ17B evoked currents were sensitive to the α7 antagonist MLA (10 nmol/L), which completely blocked the native α7 current, and the inhibitory effect can be washed out ( Figure 5A ). We further tested whether the Br-IQ17B-evoked native α7 current can be augmented in the presence of the PAM PNU-120596. A low concentration of ACh (10 mmol/L) evoked an observable α7 
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Acta Pharmacologica Sinica npg current in neurons that could be robustly increased in the presence of PNU-120596 (1 mmol/L) ( Figure 5B ). Similarly, a low concentration of Br-IQ17B (100 nmol/L) activated a small current that was significantly enhanced by the co-application of PNU-120596 (1 mmol/L), further confirming that the agonist Br-IQ17B can activate native neuronal α7 current ( Figure 5B ).
Enhanced phosphorylation of ERK signaling by Br-IQ17B in PC12 cells
The activation of native α7 nAChR results in enhanced ERK (extracellular signal-regulated kinases) phosphorylation and signaling that is implicated in the regulation of a variety of physiological functions such as cognition enhancement [35] . To test whether Br-IQ17B had any effect on ERK signaling, we evaluated ERK phosphorylation upon α7 activation in rat PC12 cells, which have intact ERK signaling and robustly expressed pathway components. Because α7 nAChR is rapidly desensitized upon activation, agonist-evoked responses are not easily detectable by conventional methods that are insufficient for the measurement of rapid effects. To overcome this shortcoming, PNU-120596 has successfully been used as a tool to slow the receptor desensitization, thus leading to easy detection of compound response. As shown in Figure 6A , the pre-incubation of PC12 cells with PNU-120596 for 10 min only caused a slight increase of the basal ratio of phosphorylated ERK (pERK1 and pERK2) over total ERK (tERK). In contrast, the pre-incubation of the PAM PNU-120596 with Br-IQ17B (0.01-10 mmol/L) for an additional 7 min significantly increased the pERK/tERK ratio in a concentration-dependent manner ( Figure 6A ). The maximal increase of the pERK/tERK ratio was approximately 3-4 fold compared with either the blank control or the pre-incubation control without Br-IQ17B.
To further confirm whether Br-IQ17B-induced ERK1/2 phosphorylation was mediated by the activation of α7 nAChR, several tool compounds including the selective antagonist MLA (100 nmol/L), the selective α7 agonist PNU-282987 (1 µmol/L), and the traditional non-selective α7 agonist nicotine (10 µmol/L) were utilized to test any specific activation of ERK signaling by Br-IQ17B. As shown in Figure 6B , the incubation of MLA (100 nmol/L) significantly reversed the activation of α7 induced by the agonists, confirming that the enhanced level of pERK is α7 activity dependent.
Enhancement of GABAergic synaptic transmission by α7 nAChR agonist Br-IQ17B
In the hippocampus, α7 nAChR subunits are primarily expressed in GABAergic interneurons, therefore we predicted that the α7 nAChR agonist Br-IQ17B might have an impact on GABAergic transmission. To test this notion, we recorded spontaneously occurring inhibitory postsynaptic current (sIPSC) from CA1 pyramidal neurons that receive inputs from interneurons in response to challenges with Br-IQ17B (10 µmol/L), PNU-120596 (1 µmol/L), or a combination of Br-IQ17B and PNU-120596 ( Figure 7A and 7B). To block glutamatergic synaptic transmissions and muscarinic AChR, spontaneous IPSCs were recorded in the presence of glutamate receptor antagonists (CNQX 5 μmol/L, APV 10 μmol/L) and a muscarinic receptor antagonist (atropine 5 μmol/L). When applied alone for 10 min, PNU-120596 produced no detectable changes in the average frequency or amplitude of sIPSC at the population level ( Figure 7B and 7C) (baseline activity at 4.5±0.7 Hz vs 4.6±0.7 Hz in the presence of PNU-120596; n=6, P>0.05; amplitude of 30.8±6.8 pA vs 30.6±4.7 pA in the presence of PNU-120596; n=6, P>0.05). In contrast, in the combined presence of Br-IQ17B and PNU120596, the peak amplitudes of IPSC events of individual neurons were significantly increased from 1.3 to 4.9 times in 5 out of 6 neurons recorded (P<0.0001) compared with control or PNU120596 alone ( Figure 7B and 7C) . After the co-application of PNU-120596 with Br-IQ17B for 1-5 min, the IPSC frequency also increased from 4.6±0.7 Hz to 7.8±0.7 Hz (n=6, P<0.01), and the combined effects of both Br-IQ17B and PNU120596 could be completely washed out ( Figure 7D ). For one neuron out of six, the co-application of Br-IQ17B and PNU-120596 promoted IPSC frequency without affecting IPSC amplitude (25.3±1.4 pA vs 25.9±1.2 pA). These results demonstrate that α7 nAChR activation by the novel agonist Br-IQ17B enhances synaptic transmissions in hippocampal neurons.
To further examine if the enhancement of IPSC resulted from an increase of GABAergic synaptic transmission, we tested the effect of Br-IQ17B on GABA A receptors with combinations of α1β3γ2, α2β3γ2, and α3β3γ2, which are the major subtypes in the brain [36, 37] . Although the α5 subunit accounts for less than 5% of GABA A receptors in brain, we also tested the selectivity on α5β3γ2 because the α5 subtype is primarily localized in the hippocampus [38] . As shown in Figure 8 , after pre-incubation for 1 min, Br-IQ17B (100 µmol/L) had no observable effects on any of the four subtypes and displayed no allosteric modulation when co-applied with 1 µmol/L GABA. These results show that enhanced GABAergic synaptic transmission likely resulted from the direct activation of α7 nAChR by Br-IQ17B.
Discussion
The goal of this study was to identify novel potent α7 nAChR agonists. Using electrophysiology as a primary screen, we identified the novel and potent compound Br-IQ17B from a series of indolizine derivatives; this compound selectively activates α7 nAChR and enhances synaptic transmission in vitro. Our α7 agonist Br-IQ17B, N-[(3R)-1-azabicyclo[2,2,2]oct-3-yl]-5-bromoindolizine-2-carboxamide, adds a novel tool in the field that may help understand new aspects of α7 nAChR function and also provides the potential for the development of novel therapy. Br-IQ17B exhibits some typical characteristics of α7 agonists reported in literature. One of the key characteristics is that the sustained exposure of Br-IQ17B progressively prevented ACh from activating α7 nAChR in Xenopus oocytes, whereas the pre-incubation of low concentration of Br-IQ17B potentiated ACh-mediated current. The most plausible explanation is the co-agonistic behavior of agonists binding at low concentrations, as previously reported for tubocurarine and ACh at α3β4 nAChRs [39] . In this study, we selected compound EVP-6124 as a ref- Furthermore, the concentration of EVP-6124 needed to reach 30% of the response (maximal response of EVP-6124) of ACh is 3 μmol/L, whereas for Br-IQ17B it is only 1.5 μmol/L. All of these findings suggest that Br-IQ17B may have advantages over EVP-6124. The identification of selective α7 agonists for CNS therapy is a huge challenge in the field; three different α7 agonists in phase I clinical studies, PHA-543613, PHA-568487, and CP-810123 were recently discontinued due to non-sustained ventricular tachycardia [23] , and the nonspecific nicotinic ligand varenicline has been associated with serious adverse cardiovascular events [24] . It is not known whether these cardiovascular events are related to the activation of α7 nAChR or other pharmacological mechanisms, but compounds such as EVP-6124 suggest that the α7 nAChR can be targeted safely in clinical trials [21] . Because drugs with less selectivity that target multiple unintended receptors may be insufficient to prevent the incidence of side effects, especially gastrointestinal ones, it is necessary to evaluate the selectivity of Br-IQ17B on other nAChR subtypes. In the present study, we were concerned that Br-IQ17B could have activity against α3β4 and α4β2 nAChRs, which have similar distribution patterns 
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Acta Pharmacologica Sinica npg as α7 nAChR in CNS [33] , and the nonspecific nicotinic ligands always have cross reactivity on these receptors (eg, nicotine, varenicline). In oocytes, Br-IQ17B showed no detectable agonist activity at up to 100 μmol/L toward either the α3β4 and α4β2 subtypes and very weak antagonist activity against α3β4 (IC 50 ≈381 μmol/L).
The 5-HT 3A belongs to the superfamily of ligand-gated ion channels. Significant sequence homology between 5-HT 3A and α7 nAChR including the ligand-binding domain can lead to the cross-reactivity of certain compounds (eg, tropisetron) [27] . Br-IQ17B inhibited 5-HT-induced current but did not evoke currents when applied alone. The antagonist activity of Br-IQ17B against 5-HT 3A receptors is likely a common property of α7 nAChR agonists, such as that reported for AZD0328 [40] and EVP-6124 [41] , which are still in clinical development. Stimulating α7 nAChR increases intracellular Ca 2+ , either directly or via voltage-gated calcium channels, and leads to the activation of Raf [42] and the subsequent activation of the ERK1/2 signaling pathway, thus allowing the phosphorylation of cytoplasmic ERK substrates [43] . The ERK1/2 pathway is a central component in signal transduction regulating synaptic targets to control plasticity, and it is implicated in the processes of learning and memory [44] . PC12 cells express native α7 nAChR and are utilized for measuring the activation of native α7 nAChR [45, 46] . Not only the non-specific nAChRs agonist nicotine but also the selective α7 nAChR agonist A-582941 have been proposed to stimulate the phosphorylation of ERK1/2 both in vitro and in vivo [47] . In our study, we assessed the phosphorylation of ERK1/2 in response to the activation of α7 nAChR by Br-IQ17B within PC12 cells, and a significant concentration-dependent increase in ERK1/2 phosphorylation was observed, indicating that the ERK1/2 pathway is a down- stream effector of α7 activation.
It has well been established that within the rat hippocampus, α7 nAChR is located predominantly in interneurons where it modulates GABAergic synaptic transmission involved in sensory gating [48] . Deficits in auditory sensory gating can lead to an inability to filter out extraneous signals from meaningful sensory inputs, resulting in a state of sensory overload, which contributes to the attentional and cognitive deficits in CNS diseases, most convincingly in schizophrenia [49] . It has been shown that the α7 nAChR partial agonist GTS-21 [3-(2,4)-dimethoxybenzilidine anabaseine], also known as DMXB-A, appears to be safe and promising for improving P50 gating deficits and attention, and it significantly improves neurocognition in schizophrenia patients with antipsychotic drugs [50, 51] . GABA is an inhibitory synaptic transmitter, and its decreased release can lead to the disinhibition of sensory gating (eg, the deficit of P50 auditory-evoked potential gating is indicated in some schizophrenic patients). To evaluate the ability of Br-IQ17B to modulate GABAergic synaptic transmission, we recorded sIPSC in pyramidal neurons in acutely isolated rat hippocampal slices. The spontaneous GABAergic synaptic events were recorded for 3 to 5 min under baseline conditions, followed by a 10-min pre-incubation of PNU-120596 before the addition of Br-IQ17B for 5 min. In agreement with the previously reported role of α7 nAChR in the hippocampus, there was no detectable change in synaptic activity after the application of PNU-120596 alone, whereas the bath application of 10 μmol/L Br-IQ17B doubled the frequency and increased the amplitude significantly.
In conclusion, we identified Br-IQ17B as a novel and selective α7 nAChR agonist that exhibits favorable potency and efficacy. Br-IQ17B is a prominent candidate that provides opportunities for further investigations in CNS pharmacology. It also serves as a suitable tool for characterizing the role of α7 nAChR in CNS function, and it may have the potential for development into new therapy for CNS disorders.
